Renata Guimarães Ferreira Alvim

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Tecnologia

Unidade:

Coordenação dos Programas de Pós-Graduação de Engenharia

Departamento:

Programa de Engenharia Química/COPPE

Universidade Federal do Rio de Janeiro
Engenharia Química | Doutorado | 2019 - 2023

Universidade Federal do Rio de Janeiro
ENGENHARIA de Processos Quimicos e Bioquimicos | Mestrado | 2017 - 2019

Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro
| Ensino Profissional de nível técnico | 2007 - 2011

Nenhum laboratório cadastrado

(100.00% artigos com DOI)

Exibir resultado(s)

Buscar

Titulo	DOI	Ano
Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection	10.1038/s41598-023-43263-y	2023
Conformational stability of SARS-CoV-2 glycoprotein spike variants	10.1016/j.isci.2022.105696	2023
From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics	10.1016/j.bej.2022.108537	2022
Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum	10.3389/fimmu.2022.884760	2022
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study	10.3389/fimmu.2022.918896	2022
Polyclonal F(ab?)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency	10.1016/j.isci.2021.103315	2021
Process intensification for the production of yellow fever virus-like particles as potential recombinant vaccine antigen	10.1002/bit.27864	2021
Zika virus-like particles (VLPs): Stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform	10.1016/j.vaccine.2019.05.064	2019

Exibindo 1 a 8 de 8 resultados

(0.00% eventos com DOI)

Exibir resultado(s)

Buscar

Titulo	DOI	Ano
CHO SINGLE CELL SUBCLONING AND STABILITY OVER PROLONGED PASSAGING IN THE PRESENCE AND ABSENCE OF SELECTION PRESSURE		2017
Development of a trivalent adjuvanted sub-unit vaccine candidate for Covid-19: From antigen expression to Ind-enabling CMC and preclinical studies		2024
Development of perfusion processes for mAb production aiming at high cell densities sustained by low cell-specific perfusion rates		2018
Expression of Zika virus-like particles by different mammalian cell lines		2016
Perfusion process for the production of a new, VLP-based yellow fever vaccine candidate		2019
PRODUCTION AND PURIFICATION OF ZIKA AND YELLOW FEVER VIRUS-LIKE PARTICLES (VLPS) EXPRESSED IN MAMMALIAN CELLS		2017
Production of Zika virus-like particles (VLPs) by perfusion processes		2019
Towards updatable, multivalent Covid vaccines: A platform process to produce trimeric spike protein of SARS-COV-2 variants expressed in HEK293 stable cell clones		2022
Upstream process development for the production of zika and yellow fever virus-like particles (VLPs)		2018
Virus-like particles (VLPs) as a platform for the development of yellow fever and Zika virus vaccine candidate		2018

Exibindo 1 a 10 de 10 resultados